Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
It was also mentioned yesterday:
CC is referring to slide 13: Toxicities with AVA6000 Demonstrate a Dose Relationship
“And so this table then describes for you a critical observation, as it provides then our first evidence that using a lower dose, and potentially shortening the interval between doses to every two weeks could enhance the anti-tumour activity by delivering more drug, increasing the dose intensity but with little to no severe toxicity. There are examples of this kind of approach in the clinic. Probably the most relevant here is the taxane Paclitaxel in the field of oncology. When Paclitaxel is administered in some settings in an every three-week regimen at a higher dose it's highly toxic, it's effective. However, when it was moved to an every weekly regimen with a lower dose, the toxicity was minimised and actually enhanced the activity. This weekly regimen is used more in the clinic, both are still used. But this is the rationale for these new dose cohorts of every two weeks dosing and it's based on the observations in this slide.”
https://youtu.be/eqj0hhgmX6U?si=tER5X1gdtec3L9Cd
Bella , I'm going from what happened with my sister in law, it was breast cancer but she was given lots of options but stuck with "traditional" chemo and had an absolutely awful experience with the horrendous side effects.
He'd be given options of applicable trials from his physician when given the horrible prognosis.
Don't think he'd be applicable either for ava6k with dose expansion and phase 2 happening in America too it may not be an option in the UK soon.
Think I'll just repeat this over and over all day everyday.
It's working as designed i.e when encountering a fap rich environment dox is cleaved.
Next phase is to identify the best cancer type to target and then see if it's efficacious.
It's cleaving dox a drug that's been in use for 50 years. In the safety and tolerability study phase 1 efficacy has already been observed.
Will it been seen in phase 2 targeting tumours that are selected as a final tumour target for the drug?
These three twats would have you believe it won't.
Make up your own mind with the factual evidence to date.
It's working as designed i.e when encountering a fap rich environment dox is cleaved.
Next phase is to identify the best cancer type to target and then see if it's efficacious.
It's cleaving dox a drug that's been in use for 50 years. In the safety and tolerability study phase 1 efficacy has already been observed.
Will it been seen in phase 2 targeting tumours that are selected as a final tumour target for the drug?
These three twats would have you believe it won't.
Make up your own mind with the factual evidence to date.
They don't care, they've never watched a presentation or read an RNS properly.
Perpetual fud is all they are interested in.
We know pre|CISION works as intended I posted that yesterday for the data, which is fact.
We know pre|CISION works